Search clinical trials for: immediate release methylphenidate hydrochloride

Total 535 results

Massachusetts General Hospital
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Completed

An Open Label Phase I/II Study of Dopamine Transporter Receptor Occupancy With OROS and Immediate Release Methylphenidate as Measured With C-11 Altropane in Human Subjects

Healthy Volunteers

United States
The University of Texas Health Science Center,...
National Institute of Mental Health (NIMH)

Completed

Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children

Autism | Attention Deficit Disorder With Hyperactivity

United States
Hangzhou Highlightll Pharmaceutical Co., Ltd

Completed

Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects

Atopic Dermatitis

China
Novartis Pharmaceuticals

Completed

Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder

Attention Deficit/Hyperactivity Disorder

Germany, United States, Belgium, Colombia, Denmark, Sweden
Heptares Therapeutics Limited
Quotient Clinical

Completed

Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation

Alzheimer's Disease

United Kingdom
GlaxoSmithKline
Quotient Clinical

Completed

A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses

Autoimmune Diseases

United Kingdom
GlaxoSmithKline
Quotient Sciences

Completed

A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772

Autoimmune Diseases

United Kingdom
Milton S. Hershey Medical Center
Children's Miracle Network

Terminated

Effects of Evening Dose of Immediate Release Methylphenidate on Sleep in Children With ADHD

Behavioral Insomnia of Childhood | Attention Deficit Disorder With Hyperactivity

United States
Prof. Huss

Terminated

Adherence to Stimulant Treatment in Attention-Deficit Hyperactivity Disorder (ADHD) Patients (ASTA) (ASTA)

ADHD

Germany
Pfizer

Completed

A Study To Evaluate Different Formulations Of PF-06865571 In Healthy Subjects

Healthy

Belgium
Pfizer

Completed

A Sub Study to Evaluate the Study Medication (Etrasimod) Using Wearable Sensors in Healthy Participants

Healthy Participants

Belgium
Purdue Pharma LP

Terminated

Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) (RE-DAX)

Attention-Deficit/Hyperactivity Disorder

United States
Massachusetts General Hospital
Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

A Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults

Healthy

United States
GlaxoSmithKline

Completed

A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy Subjects

Diabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus

United States
Pfizer

Completed

A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961

Healthy Subjects

United States
Hospital de Clinicas de Porto Alegre
Federal University of Rio Grande do Sul; Conselho Nacional de Desenvolvimento... and other collaborators

Recruiting

Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder

Attention Deficit Disorder With Hyperactivity

Brazil
Sheba Medical Center

Completed

The Effect of Methylphenidate Treatment in Familial Attention Deficit/Hyperactivity Disorder (ADHD)

ADHD Predominantly Inattentive Type | Attention Deficit/Hyperactivity Disorder Combined Type | ADHD Predominantly Hyperactivity Type | ADHD-not Other Specified

Israel
GlaxoSmithKline

Completed

First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050

Diabetes Mellitus, Type 2

United States
Mahidol University

Not yet recruiting

The Study of Efficacy and Safety of Generic Methylphenidate Prolong-released Comparison With Original

Adhd
University Hospital, Strasbourg, France

Recruiting

EEG-MRI Imaging of Methylphenidate Effects in Adult ADHD and Attentional Symptoms in Mood Disorders (ImAteM-TDA)

Adult ADHD | Adult-onset ADHD With Mood Disorder

France
Monash Medical Centre
Monash University

Recruiting

FASST - Fetal Alcohol Spectrum Stimulant Trial (FASST)

Fetal Alcohol Spectrum Disorders

Australia
Bayer

Completed

A Study to Learn How the Study Treatment BAY3283142 Taken as Single Dose by Mouth Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function of Similar Age, Gender, and Weight

Renal Impairment | Chronic Kidney Disease | Healthy Volunteers

Germany
Allameh Tabatabai University

Completed

Computer-assisted Cognitive Rehabilitation (CACR), Placebo CACR and Psycho-stimulants in the Treatment of ADHD

Attention Deficit Disorder With Hyperactivity

Iran, Islamic Republic of
ApoPharma

Completed

Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy Volunteers

Healthy

Canada
Pfizer
ViiV Healthcare

Completed

Study to Estimate the Pharmacokinetics, Bioavailability and Effect of Food on Single Dose Modified-release Lersivirine 500 mg in Healthy Subjects

Healthy Volunteer

Belgium
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

Attention-Deficit/Hyperactivity Disorder (ADHD)

United States
AstraZeneca

Withdrawn

A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects

Healthy Male Subjects | Pharmacokinetics | Safety | Food Effect

United Kingdom
Novartis Pharmaceuticals

Completed

A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

United States
McNeil Consumer & Specialty Pharmaceuticals, a...

Completed

A Safety and Effectiveness Study of Methylphenidate HCl Extended-release Tablets in Adults With Attention Deficit Hyperactivity Disorder

Attention Deficit Disorder With Hyperactivity
McNeil Consumer & Specialty Pharmaceuticals, a...

Completed

A Long-Term Safety Study to Evaluate Methylphenidate HCL Tablets at Multiple Dose Levels in Adults With Attention Deficit Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder
Janssen Korea, Ltd., Korea

Completed

An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Disorder With Hyperactivity
Luye Pharma Group Ltd.

Recruiting

A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder.

Generalized Anxiety Disorder

China
Sarfez Pharmaceuticals, Inc.

Recruiting

Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder

Heart Failure | Overactive Bladder | Incontinence

United States
GlaxoSmithKline

Completed

Healthy Volunteer Study Using 3 Different Formulations of Firategrast

Multiple Sclerosis, Relapsing-Remitting

Australia
KalVista Pharmaceuticals, Ltd.

Completed

Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations

Hereditary Angioedema

United Kingdom
McMaster University
Purdue Pharma, Canada

Completed

A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity

Generalized Anxiety Disorder | Attention Deficit Hyperactivity Disorder | Social Anxiety Disorder | Panic Disorder | Agoraphobia

Canada
Pfizer

Withdrawn

A 6-week Study to Evaluate the Safety and Efficacy of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD

Attention Deficit Hyperactivity Disorder
Massachusetts General Hospital
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Completed

Study Examining Repeat Dosing of OROS® Methylphenidate (CONCERTA®) and Immediate Release Methylphenidate in Healthy Adults

Healthy

United States
Massachusetts General Hospital
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Completed

A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy Of Two Long-Acting Formulations of Methylphenidate in Adults

Healthy Volunteers

United States
Massachusetts General Hospital
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Completed

Naturalistic Substitution of Concerta in Adult Subject With ADHD Receiving Immediate Release Methylphenidate

Attention Deficit Hyperactivity Disorder

United States
Janssen-Cilag International NV

Completed

A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder

Attention Deficit/ Hyperactivity Disorder

France, Belgium, Germany, Spain, Switzerland, Denmark, Finland, Netherlands, Norway, Sweden, United Kingdom
Rhodes Pharmaceuticals, L.P.

Completed

Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD

ADHD | Attention Deficit Hyperactivity Disorder

United States
Xian-Janssen Pharmaceutical Ltd.

Completed

A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants

Attention Deficit Hyperactivity Disorder (ADHD)

China
Rhodes Pharmaceuticals, L.P.

Completed

Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting

ADHD | Attention Deficit Hyperactivity Disorder

United States
Shanghai Mental Health Center

Not yet recruiting

Efficacy and Safety of Toluedesvenlafaxine Hydrochloride Extended-release Tablets in Somatic Symptoms of Depression

Somatic Symptom

China
Alexion Pharmaceuticals

Completed

A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants

Healthy

United States
Alexion

Recruiting

A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants

Healthy Participants

United Kingdom
McNeil Consumer & Specialty Pharmaceuticals, a...

Completed

Community-based Study Comparing Extended-release Methylphenidate and Atomoxetine in Children With Attention-deficit Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder
APOGEPHA Arzneimittel GmbH

Completed

Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity

Urologic Diseases | Urinary Incontinence | Urinary Bladder, Neurogenic | Neurogenic Urinary Bladder Disorder | Bladder Disorder, Neurogenic | Urinary Bladder Disorder, Neurogenic | Neurogenic Bladder Disorder | Urinary Bladder Neurogenic Dysfunction | Overactive Detrusor Function

Romania, Austria, Germany
Astellas Pharma Global Development, Inc.

Completed

To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients (ASTOUND)

Kidney Transplantation

United States

3

Subscribe